Literature DB >> 25500881

The genetics of hepatitis C virus underlie its ability to escape humoral immunity.

Jay K Kolls, Gyongyi Szabo.   

Abstract

Hepatitis C virus (HCV) is a leading cause of chronic liver disease, and efforts to develop therapeutic vaccine strategies have been limited by immune escape due to HCV variants that are resistant to current vaccines or HCV variants that rapidly acquire new resistance-conferring mutations. Recently, the crystal structure of the viral envelope protein E2 region was resolved as well as how E2 docks to the host CD81 protein; therefore, antibodies that block this interaction should prevent viral entry into host cells. In this issue of the JCI, Bailey and colleagues show that immune escape of HCV can occur by naturally occurring polymorphisms in E2 that are distinct from those at mapped sites of antibody binding. These data reveal alternative mechanisms of resistance that need to be considered in both natural viral escape as well as in rationale vaccine design against HCV.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25500881      PMCID: PMC4382271          DOI: 10.1172/JCI79424

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  8 in total

1.  A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection from The Liver Meeting 2013: The 64th Annual Meeting of the American Association for the Study of Liver DiseasesNovember 1-5, 2013 • Washington DCSpecial Reporting on:• Simeprevir plus Sofosbuvir with or without Ribavirin Produces High SVR Rates in Genotype 1 HCV Infection• Novel Interferon- and Ribavirin-Free Regimen Results in SVR12 Rates of Over 90% in HCV Genotype 1b Infection• Studies Confirm Efficacy of Adjunctive Simeprevir in Difficult-to-Treat HCV Genotype 1 Subpopulations• All-Oral Therapy with Sofosbuvir Plus Ribavirin Produces High SVR Rates in Patients Coinfected with HCV and HIV• Faldaprevir Combined with Pegylated Interferon and Ribavirin Demonstrates High Efficacy in DifficuIt-to-Treat HCV Infection• Once Daily Sofosbuvir/Ledipasvir Combination Elicits Rapid Decline in HCV RNAPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDWeill Cornell Medical CollegeNew York, New York.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-01

2.  Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step.

Authors:  Michelle C Sabo; Vincent C Luca; Jannick Prentoe; Sharon E Hopcraft; Keril J Blight; Minkyung Yi; Stanley M Lemon; Jonathan K Ball; Jens Bukh; Matthew J Evans; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

3.  Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance.

Authors:  Justin R Bailey; Lisa N Wasilewski; Anna E Snider; Ramy El-Diwany; William O Osburn; Zhenyong Keck; Steven K H Foung; Stuart C Ray
Journal:  J Clin Invest       Date:  2014-12-15       Impact factor: 14.808

4.  Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses.

Authors:  William O Osburn; Anna E Snider; Brittany L Wells; Rachel Latanich; Justin R Bailey; David L Thomas; Andrea L Cox; Stuart C Ray
Journal:  Hepatology       Date:  2014-04-29       Impact factor: 17.425

5.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Authors:  Nezam Afdhal; Stefan Zeuzem; Paul Kwo; Mario Chojkier; Norman Gitlin; Massimo Puoti; Manuel Romero-Gomez; Jean-Pierre Zarski; Kosh Agarwal; Peter Buggisch; Graham R Foster; Norbert Bräu; Maria Buti; Ira M Jacobson; G Mani Subramanian; Xiao Ding; Hongmei Mo; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Alessandra Mangia; Patrick Marcellin
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

6.  Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90.

Authors:  Terence N Bukong; Fatemeh Momen-Heravi; Karen Kodys; Shashi Bala; Gyongyi Szabo
Journal:  PLoS Pathog       Date:  2014-10-02       Impact factor: 6.823

7.  Chronic hepatitis C virus (HCV) disease burden and cost in the United States.

Authors:  Homie Razavi; Antoine C Elkhoury; Elamin Elbasha; Chris Estes; Ken Pasini; Thierry Poynard; Ritesh Kumar
Journal:  Hepatology       Date:  2013-05-06       Impact factor: 17.425

8.  Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423.

Authors:  Zhen-yong Keck; Allan G N Angus; Wenyan Wang; Patrick Lau; Yong Wang; Derek Gatherer; Arvind H Patel; Steven K H Foung
Journal:  PLoS Pathog       Date:  2014-08-14       Impact factor: 6.823

  8 in total
  4 in total

1.  Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability.

Authors:  Timothy T Spear; Timothy P Riley; Gretchen E Lyons; Glenda G Callender; Jeffrey J Roszkowski; Yuan Wang; Patricia E Simms; Gina M Scurti; Kendra C Foley; David C Murray; Lance M Hellman; Rachel H McMahan; Makio Iwashima; Elizabeth Garrett-Mayer; Hugo R Rosen; Brian M Baker; Michael I Nishimura
Journal:  J Leukoc Biol       Date:  2016-02-26       Impact factor: 4.962

2.  TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors.

Authors:  Timothy T Spear; Glenda G Callender; Jeffrey J Roszkowski; Kelly M Moxley; Patricia E Simms; Kendra C Foley; David C Murray; Gina M Scurti; Mingli Li; Justin T Thomas; Alexander Langerman; Elizabeth Garrett-Mayer; Yi Zhang; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-02-03       Impact factor: 6.968

Review 3.  RNA Viruses and RNAi: Quasispecies Implications for Viral Escape.

Authors:  John B Presloid; Isabel S Novella
Journal:  Viruses       Date:  2015-06-19       Impact factor: 5.048

4.  Comparison of Interferon-Gamma (IFNG) +874 T/A Single Nucleotide Polymorphism in Hepatitis C Virus Infected Patients and Non-Infected Controls in Mashhad, Iran.

Authors:  Sina Rostami; Alireza Pasdar; Sina Gerayli; Hamed Hatami; Samaneh Sepahi; Fatemeh Nategh; Mojtaba Meshkat; Seyed Mousalreza Hoseini; Mitra Ahadi; Hamid Reza Sima; Hasan Vosughinia; Mohammad Reza Sarvghad; Abbas Esmaeelzade; Hosein Nomani; Homan Mosanan Mozafari; Fariba Rezai Talab; Mohammad Taghi Shakeri; Zahra Meshkat
Journal:  Iran J Pathol       Date:  2017-05-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.